N V Khachanova - JoVE Visualize

Showing results (21-30 of 31) with videos related to

Pageof 4

Sort By:

Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova|December 5, 2013

[The first experience of the use the Russian Β-interferon-1b biosimilar (infibeta) in the daily practice of the Moscow Center of Multiple Sclerosis]E V Popova, A N Boĭko, M V Davydovskaia, et al.

Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova|September 7, 2012

[Results of a comparative clinical trial of the Russian Β - interferon-1b bioanalogue (infibeta)]E V Popova, A N Boĭko, A V Vasil'ev, et al.

Zhurnal Voprosy Neirokhirurgii Imeni N. N. Burdenko|March 16, 2016

[A correlation between diffusion kurtosis imaging and the proliferative activity of brain glioma]A S Tonoyan, I N Pronin, D I Pitshelauri, et al.

Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova|March 3, 2017

[Clinical guidelines for the use of dimethyl fumarate in relapsing-remitting multiple sclerosis]V M Alifirova, A N Boiko, Ya V Vlasov, et al.

Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova|April 24, 2020

[Updated recommendations of the Council of Experts on the use and safety of alemtuzumab (Lemtrada)]N V Khachanova, K Z Bakhtiyarova, A N Boyko, et al.

Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova|June 9, 2012

[Efficacy and tolerability of long-term using of glatimer acetate (copaxone): a 10 year-study in the Moscow Municipal Multiple Sclerosis center]A N Boĭko, M V Davydovskaia, T L Demina, et al.

Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova|June 9, 2012

[The comparative study of efficacy and tolerability of intramuscular introduction of beta-interferon-1a in adults and adolescents with remitting multiple sclerosis]A N Boĭko, T T Batysheva, O V Bykova, et al.

Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova|August 31, 2018

[Provision of alemtuzumab safety is one of the main components of pharmacovigilance]N V Khachanova, K Z Bakhtiyarova, A N Boyko, et al.

Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova|September 16, 2011

[Data of MRI and neuropsychological tests predict the course of typical remitting multiple sclerosis during five years]B T Mugutdinova, A N Boĭko, S V Serkov, et al.

Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova|August 1, 2022

[New opportunities in the treatment of patients with multiple sclerosis (Resolution of the Council of Experts on April 23, 2022, Moscow, JSC «BIOCAD»)]N N Spirin, Ya V Vlasov, M N Zakharova, et al.

Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:

Pageof 4

Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova|December 5, 2013

[The first experience of the use the Russian Β-interferon-1b biosimilar (infibeta) in the daily practice of the Moscow Center of Multiple Sclerosis]E V Popova, A N Boĭko, M V Davydovskaia, et al.

Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova|September 7, 2012

[Results of a comparative clinical trial of the Russian Β - interferon-1b bioanalogue (infibeta)]E V Popova, A N Boĭko, A V Vasil'ev, et al.

Zhurnal Voprosy Neirokhirurgii Imeni N. N. Burdenko|March 16, 2016

[A correlation between diffusion kurtosis imaging and the proliferative activity of brain glioma]A S Tonoyan, I N Pronin, D I Pitshelauri, et al.

Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova|March 3, 2017

[Clinical guidelines for the use of dimethyl fumarate in relapsing-remitting multiple sclerosis]V M Alifirova, A N Boiko, Ya V Vlasov, et al.

Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova|April 24, 2020

[Updated recommendations of the Council of Experts on the use and safety of alemtuzumab (Lemtrada)]N V Khachanova, K Z Bakhtiyarova, A N Boyko, et al.

Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova|June 9, 2012

[Efficacy and tolerability of long-term using of glatimer acetate (copaxone): a 10 year-study in the Moscow Municipal Multiple Sclerosis center]A N Boĭko, M V Davydovskaia, T L Demina, et al.

Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova|June 9, 2012

[The comparative study of efficacy and tolerability of intramuscular introduction of beta-interferon-1a in adults and adolescents with remitting multiple sclerosis]A N Boĭko, T T Batysheva, O V Bykova, et al.

Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova|August 31, 2018

[Provision of alemtuzumab safety is one of the main components of pharmacovigilance]N V Khachanova, K Z Bakhtiyarova, A N Boyko, et al.

Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova|September 16, 2011

[Data of MRI and neuropsychological tests predict the course of typical remitting multiple sclerosis during five years]B T Mugutdinova, A N Boĭko, S V Serkov, et al.

Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova|August 1, 2022

[New opportunities in the treatment of patients with multiple sclerosis (Resolution of the Council of Experts on April 23, 2022, Moscow, JSC «BIOCAD»)]N N Spirin, Ya V Vlasov, M N Zakharova, et al.

Pageof 4